mAbxience Partners With OncoPrecision on ONC001
The agreement covers development and GMP manufacturing of OncoPrecision's lead antibody-drug conjugate candidate ahead of a planned phase 1 trial.
Updated on Nov. 18, 2026 in Biotech

mAbxience and OncoPrecision announced an investment, development, and manufacturing agreement for ONC001, OncoPrecision's lead antibody-drug conjugate candidate, on November 18, 2026. mAbxience has made a strategic investment in OncoPrecision, and its CEO, Jurgen Van Broeck, will join OncoPrecision's board as an observer.
Why it matters
The deal moves ONC001, a CD64-targeting ADC aimed at monocytic acute myeloid leukemia and chronic myelomonocytic leukemia, closer to first-in-human studies. Financial terms of the investment were not disclosed.
The announcement contains no quantitative clinical or financial figures, as the investment terms were not disclosed. The program's stated scope runs from cell line development through the first GMP batch for clinical use.
The players
mAbxience
mAbxience is a biopharmaceutical contract development and manufacturing organization that is supplying development and GMP manufacturing services for ONC001.
OncoPrecision
OncoPrecision is a New York City-based company developing ONC001, its lead CD64-targeting antibody-drug conjugate candidate.
Jurgen Van Broeck
Jurgen Van Broeck is the chief executive of mAbxience and will join OncoPrecision's board of directors as an observer.
The details
Under the agreement, mAbxience will handle development of the ONC001 antibody portion, from cell line development through process and analytical development, and will manufacture GMP-grade material to support the planned phase 1 trial. ONC001 was first publicly disclosed in an oral presentation at the 2025 ASH Annual Meeting.
Timeline
2025 ASH Annual Meeting: ONC001 first publicly disclosed in an oral presentation.
November 18, 2026: mAbxience and OncoPrecision announced the ONC001 agreement.
Roadmap
ONC001 is one of a small number of CD64-targeting antibody-drug conjugates advancing toward the clinic for monocytic leukemias. The mAbxience partnership reflects a broader pattern of biotech developers outsourcing antibody manufacturing to contract organizations as candidates approach phase 1.
For patients with monocytic acute myeloid leukemia or chronic myelomonocytic leukemia, the agreement advances a candidate that is not yet in human testing, so no treatment access changes immediately. The news matters most to researchers and investors tracking how early-stage cancer biotechs secure manufacturing capacity.
The takeaway
Early-stage cancer biotechs increasingly depend on outside manufacturing partners to move candidates toward the clinic, and partnerships like this one show how development and GMP supply can be bundled from the start.
Further reading
Explore more Biotech coverage for context on antibody-drug conjugate development and manufacturing partnerships.
Source note: This article includes information reported by BioPharm International.



